Trial reportGastroenterology2020
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
Trial report in Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 4 syntheses or guidelines pooled it, 229 citations in OpenAlex.
- Immunomodulators and Advanced Therapies for Induction of Remission in Crohn's Disease: A Systematic Review and Network Meta-Analysis.Inflammatory bowel diseases · 2026Pooled it
- Mucosal and Transmural Healing and Long-term Outcomes in Crohn's Disease.Inflammatory bowel diseases · 2025Pooled it
- Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective.United European gastroenterology journal · 2024Pooled it
- Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.The Cochrane database of systematic reviews · 2020Pooled it
- Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial.Advances in therapy · 2026Trial
- Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn's Disease: A Post Hoc Analysis of the SEAVUE Trial.Inflammatory bowel diseases · 2025Trial
- Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study.Journal of Crohn's & colitis · 2025Trial
- Induction of Endoscopic Response, Remission, and Ulcer-Free Endoscopy With Upadacitinib Is Associated With Improved Clinical Outcomes and Quality of Life in Patients With Crohn's Disease.Inflammatory bowel diseases · 2025Trial
- Beyond class switching in multi-refractory inflammatory bowel disease: Nine case reports and review of literature.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
- Early transmural response assessed by intestinal ultrasound predicts long-term clinical remission in patients with IBD: Results from the TRUST BEYOND study.Inflammatory bowel diseases · 2026Article
- Letter: Does the Association Between Mild Endoscopic Activity and Adverse Outcomes Justify Treatment Escalation in Older Adults With Inflammatory Bowel Disease?Alimentary pharmacology & therapeutics · 2026Article
- The Diagnostic Challenge of Crohn's Disease With Initial Duodenal Involvement: Two Cases and Literature Review.Immunity, inflammation and disease · 2026Review
- Escalation to biologics after corticosteroids in patients with newly diagnosed Crohn's disease in Japan: a claims analysis from 2010 to 2021.Intestinal research · 2026Article
- Magnetic resonance imaging-based simplified MaRIA scores are associated with future surgery in Crohn's disease, but modest correlation with ileo-colonoscopic inflammation limits their utility in clinical trials: results from the PROFILE trial.Journal of Crohn's & colitis · 2026Article
- Positioning of advanced therapies in patients with moderate-to-severe Crohn's disease.Singapore medical journal · 2026Review
- Stoma formation and associated risk factors in patients with Crohn's disease in an Austrian tertiary referral hospital: a retrospective explorative study of long-term follow-up.Crohn's & colitis 360 · 2026Article
- Redefining Early Intervention and the Window of Opportunity in Crohn's Disease.Gastroenterology & hepatology · 2026Article
- Improvement in small-bowel and colonic lesions observed by intestinal ultrasonography in Crohn's disease treated with risankizumab.Medicine · 2026Article
- Impact of timing on mucosal healing during restaging endoscopy in pediatric Crohn's disease: A retrospective cohort study.JPGN reports · 2026Article
- Treat-to-Target in Ulcerative Colitis: How Soon Is Now?Journal of clinical medicine · 2026Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 20 institutions in 18 countries.
Funding
Abstract
BACKGROUND &
aimsWe investigated the effects of inducing deep remission in patients with early Crohn's disease (CD).
methodsWe collected follow-up data from 122 patients (mean age, 31.2 ± 11.3 y) with early, moderate to severe CD (median duration, 0.2 years; interquartile range, 0.1-0.5) who participated in the Effect of Tight Control Management on CD (CALM) study, at 31 sites, representing 50% of the original CALM patient population. Fifty percent of patients (n = 61) were randomly assigned to a tight control strategy (increased therapy based on fecal level of calprotectin, serum level of C-reactive protein, and symptoms), and 50% were assigned to conventional management. We categorized patients as those who were vs were not in deep remission (CD endoscopic index of severity scores below 4, with no deep ulcerations or steroid treatment, for 8 or more weeks) at the end of the follow-up period (median, 3.02 years; range, 0.05-6.26 years). The primary outcome was a composite of major adverse outcomes that indicate CD progression during the follow-up period: new internal fistulas or abscesses, strictures, perianal fistulas or abscesses, or hospitalization or surgery for CD. Kaplan-Meier and penalized Cox regression with bootstrapping were used to compare composite rates between patients who achieved or did not achieve remission at the end of the follow-up period.
resultsMajor adverse outcomes were reported for 34 patients (27.9%) during the follow-up period. Significantly fewer patients in deep remission at the end of the CALM study had major adverse outcomes during the follow-up period (P = .01). When we adjusted for potential confounders, deep remission (adjusted hazard ratio, 0.19; 95% confidence interval, 0.07-0.31) was significantly associated with a lower risk of major adverse outcome.
conclusionsIn an analysis of follow-up data from the CALM study, we associated induction of deep remission in early, moderate to severe CD with decreased risk of disease progression over a median time of 3 years, regardless of tight control or conventional management strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.